Pre-made Carotuximab benchmark antibody ( Whole mAb, anti-ENG therapeutic antibody, Anti-END/HHT1/ORW1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-095-1mg	1mg	3090
GMP-Bios-ab-095-10mg	10mg	Inquiry
GMP-Bios-ab-095-100mg	100mg	Inquiry
GMP-Bios-ab-095-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Carotuximab biosimilar, Whole mAb, Anti-ENG Antibody: Anti-END/HHT1/ORW1 therapeutic antibody
INN Name	Carotuximab
Target	ENG
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	National Cancer Institute (USA);Santen Pharmaceutical;TRACON Pharmaceuticals;University of Alabama at Birmingham;University of Minnesota;Roswell Park Cancer Institute
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Fallopian tube cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Haemangiosarcoma;Choriocarcinoma;Glioblastoma;Liver cancer;Renal cell carcinoma;Soft tissue sarcoma;Breast cancer;Non-small cell lung cancer;Acute myeloid leukaemia;Colorectal cancer;Precursor B-cell lymphoblastic leukaemia-lymphoma;Wet age-related macular degeneration
Development Tech	na